The data shown below were compiled from readership statistics for 383 Mendeley readers of this research output. Click here to see the associated Mendeley record.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays
|
|---|---|
| Published in |
Journal of Medicinal Chemistry, December 2004
|
| DOI | 10.1021/jm049486a |
| Pubmed ID | |
| Authors |
Louis J. Lombardo, Francis Y. Lee, Ping Chen, Derek Norris, Joel C. Barrish, Kamelia Behnia, Stephen Castaneda, Lyndon A. M. Cornelius, Jagabandhu Das, Arthur M. Doweyko, Craig Fairchild, John T. Hunt, Ivan Inigo, Kathy Johnston, Amrita Kamath, David Kan, Herbert Klei, Punit Marathe, Suhong Pang, Russell Peterson, Sidney Pitt, Gary L. Schieven, Robert J. Schmidt, John Tokarski, Mei-Li Wen, John Wityak, Robert M. Borzilleri |
| Abstract |
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 2% |
| Germany | 1 | <1% |
| Sweden | 1 | <1% |
| Ireland | 1 | <1% |
| Japan | 1 | <1% |
| Czechia | 1 | <1% |
| Unknown | 372 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 83 | 22% |
| Researcher | 61 | 16% |
| Student > Bachelor | 41 | 11% |
| Student > Master | 40 | 10% |
| Other | 29 | 8% |
| Other | 60 | 16% |
| Unknown | 69 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 71 | 19% |
| Agricultural and Biological Sciences | 64 | 17% |
| Medicine and Dentistry | 63 | 16% |
| Biochemistry, Genetics and Molecular Biology | 61 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 5% |
| Other | 27 | 7% |
| Unknown | 78 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2024.
All research outputs
#1,362,683
of 25,837,817 outputs
Outputs from Journal of Medicinal Chemistry
#359
of 23,334 outputs
Outputs of similar age
#2,730
of 154,925 outputs
Outputs of similar age from Journal of Medicinal Chemistry
#1
of 172 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,334 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,925 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.